{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:46:44Z","timestamp":1747183604949,"version":"3.40.5"},"reference-count":11,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2024,4,6]],"date-time":"2024-04-06T00:00:00Z","timestamp":1712361600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2024,5]]},"abstract":"<jats:p>The role of Pi3K inhibitors in lymphoma is diminishing due to the adverse results from trials in indolent lymphoma, but is a one\u2010size\u2010fits\u2010all approach to drug development penalising some lymphoma subtypes and the newer generation of Pi3K inhibitors? The report by Soumerai et\u00a0al. of zandelisib with zanubrutinib in follicular and mantle cell lymphoma is an important addition to the data.<\/jats:p><jats:p>Commentary on: Soumerai et\u00a0al. Safety and efficacy of zandelisib plus zanubrutinib in previously treated follicular and mantle cell lymphomas. Br J Haematol 2024;204:1762\u20101770.<\/jats:p>","DOI":"10.1111\/bjh.19456","type":"journal-article","created":{"date-parts":[[2024,4,6]],"date-time":"2024-04-06T11:09:54Z","timestamp":1712401794000},"page":"1582-1584","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Learnings from phosphatidylinositol 3\u2010kinase inhibitors in lymphoma\u2014Moving to a model where less can be more"],"prefix":"10.1111","volume":"204","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-3094-8867","authenticated-orcid":false,"given":"Arina","family":"Martynchyk","sequence":"first","affiliation":[{"name":"Olivia Newton\u2010John Cancer Research and Wellness Centre Austin Health  Heidelberg Victoria Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0376-2559","authenticated-orcid":false,"given":"Eliza A.","family":"Hawkes","sequence":"additional","affiliation":[{"name":"Olivia Newton\u2010John Cancer Research and Wellness Centre Austin Health  Heidelberg Victoria Australia"},{"name":"School of Public Health and Preventive Medicine Monash University  Melbourne Victoria Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2024,4,6]]},"reference":[{"key":"e_1_2_4_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.19419"},{"key":"e_1_2_4_3_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.7511"},{"key":"e_1_2_4_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021006083"},{"key":"e_1_2_4_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00775"},{"key":"e_1_2_4_6_1","unstructured":"FDA.FDA briefing document for the Oncologic Drugs Advisory Committee (ODAC) Meeting April 21 2022. Phosphatidylinositol 3\u2010kinase (PI3K) inhibitors in hematologic malignancies 2022."},{"issue":"3","key":"e_1_2_4_7_1","first-page":"117","article-title":"Zandelisib and B\u2010cell lymphomas","volume":"21","author":"Zelenetz AD","year":"2023","journal-title":"Clin Adv Hematol Oncol"},{"key":"e_1_2_4_8_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.3994"},{"key":"e_1_2_4_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-08-802470"},{"key":"e_1_2_4_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30082-2"},{"key":"e_1_2_4_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-147460"},{"key":"e_1_2_4_12_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehr352"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.19456","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,4]],"date-time":"2024-11-04T08:41:44Z","timestamp":1730709704000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.19456"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,6]]},"references-count":11,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["10.1111\/bjh.19456"],"URL":"https:\/\/doi.org\/10.1111\/bjh.19456","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"type":"print","value":"0007-1048"},{"type":"electronic","value":"1365-2141"}],"subject":[],"published":{"date-parts":[[2024,4,6]]},"assertion":[{"value":"2024-03-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-03-29","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}